Table 2.
Groups | Training | Testing | Total | |
---|---|---|---|---|
Train | Validation | |||
Benign | 160 | 40 | 50 | 250 |
Malignant | 160 | 40 | 50 | 250 |
Total | 320 | 80 | 100 | 500 |
Groups | Training | Testing | Total | |
---|---|---|---|---|
Train | Validation | |||
Benign | 160 | 40 | 50 | 250 |
Malignant | 160 | 40 | 50 | 250 |
Total | 320 | 80 | 100 | 500 |